Newspaper article from our research archive:

MabCampath(R) Shown to Be Effective in Treatment of Peripheral T-Cell Lymphomas.

SAN DIEGO, December 6 /PRNewswire/ --

- First-Line Chemoimmunotherapeutic Regimen Constitutes New Approach

Data from a clinical trial presented at the American Society of Hematology 46th Annual Meeting and Exposition (ASH) demonstrated MabCampath (alemtuzumab) was effective in the first-line treatment of peripheral T-cell non Hodgkin's Lymphoma (NHL).

"Peripheral T-cell lymphomas are often associated with unfavorable clinical outcomes," explained Eckhart Weidmann, M.D., of the Department of Hematology and Oncology of Northwest Hospital, Frankfurt, Germany, "The study shows the effectiveness of MabCampath and combination chemotherapy as a first-line therapy for ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!